The RAPPORT clinical trial: interim safety analysis of combination SABR with adjuvant anti-PD1 immunotherapy in oligometastatic renal cell carcinoma
Article 2018 en
Authors
SS
Shankar Siva
MB
Mathias Bressel
MS
Mark Shaw
Abstract
1 min read
Poster: 2018 ASM / R-0117 / The RAPPORT clinical trial: interim safety analysis of combination SABR with adjuvant anti-PD1 immunotherapy in oligometastatic renal cell carcinoma by: Siva1, M. Bressel1, M. Shaw1, S. Chander1, S. Loi1, D. Pryor2, S. Sandhu1, J. Mooi1, D. Jayamanne3, T. Eade3, N. Lawrentschuk 1, D. Murphy1, J. Lewin1, B. Tran1, F. Foroudi1; 1VIC/AU, 2QLD/AU, 3NSW/AU
Shankar Siva, Mathias Bressel, Mark Shaw, Sarat Chander, Sherene Loi, David Pryor, Shahneen Sandhu, Jennifer Mooi, Dasantha Jayamanne, Thomas Eade, Nathan Lawrentschuk, Declan Murphy, Jeremy Lewin, Ben Tran, Farshad Foroudi
Shankar Siva, Mathias Bressel, Shahneen Sandhu, Bach Xuan Tran, Jennifer Mooi, Jan S. Lewin, Sherene Loi, Guy C. Toner, Daniel Moon, Jeremy Goad, Mark Shaw, Sarat Chander, Thomas Eade, Alex Guminski, Dasantha Jayamanne, David Pryor, Katharine Cuff, S. Wood, Nathan Lawrentschuk, D. Murphy
Shankar Siva, Mathias Bressel, Simon Wood, Mark Shaw, Sherene Loi, Shahneen Sandhu, Ben Tran, Arun Azad, Jeremy Lewin, Katharine Cuff, Howard Liu, Daniel Moon, Jeremy Goad, Lih‐Ming Wong, Michael Lim‐Joon, Jennifer Mooi, Sarat Chander, Declan G. Murphy, Nathan Lawrentschuk, David Pryor
Shankar Siva, Mathias Bressel, Simon Wood, Mark Shaw, Sherene Loi, Shahneen Sandhu, Ben Tran, Arun Azad, Jeremy Lewin, Katharine Cuff, Nitika Neha, Duncan Colyer, Paul J. Neeson, Howard Liu, Sarat Chander, Daniel Moon, Jeremy Goad, Declan G. Murphy, Nathan Lawrentschuk, David Pryor
Helen Dearden, Lewis Au, Daniel Wang, Lisa Zimmer, Zeynep Eroglu, Jessica L. Smith, Marcello Cuvietto, Chloe Khoo, Victoria Atkinson, Serigne Lo, Georgina V. Long, Shahneen Sandhu, Paolo A. Ascierto, Matteo S. Carlino, Douglas B. Johnson, James Larkin, Alexander M. Menzies
Discussion(0)
No comments yet. Be the first to comment.